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Abstract
Many species of tsetse flies are infected with a virus that causes salivary gland hypertrophy (SGH) symptoms associated with
a reduced fecundity and fertility. A high prevalence of SGH has been correlated with the collapse of two laboratory colonies
of Glossina pallidipes and colony maintenance problems in a mass rearing facility in Ethiopia. Mass-production of
G. pallidipes is crucial for programs of tsetse control including the sterile insect technique (SIT), and therefore requires a
management strategy for this virus. Based on the homology of DNA polymerase between salivary gland hypertrophy virus
and herpes viruses at the amino acid level, two antiviral drugs, valacyclovir and acyclovir, classically used against herpes
viruses were selected and tested for their toxicity on tsetse flies and their impact on virus replication. While long term per os
administration of acyclovir resulted in a significant reduction of productivity of the colonies, no negative effect was
observed in colonies fed with valacyclovir-treated blood. Furthermore, treatment of a tsetse colony with valacyclovir for 83
weeks resulted in a significant reduction of viral loads and consequently suppression of SGH symptoms. The combination of
initial selection of SGHV-negative flies by non-destructive PCR, a clean feeding system, and valacyclovir treatment resulted
in a colony that was free of SGH syndromes in 33 weeks. This is the first report of the use of a drug to control a viral infection
in an insect and of the demonstration that valacyclovir can be used to suppress SGH in colonies of G. pallidipes.
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Introduction
In sub-Saharan Africa, tsetse flies (Glossina spp.) are the vectors
of two debilitating diseases, human sleeping sickness and the cattle
disease nagana [1] and are a major constraint to the development
of sustainable livestock production systems and the reduction of
hunger and poverty [2]. Due to the lack of vaccines, the difficulty
of drug treatment for sleeping sickness, and the development of
resistance to the available trypanocidal drugs for nagana [3],
vector control remains the most efficient strategy for the
sustainable management of these diseases [4].
The successful eradication of Glossina austeni from Unguja
Island (Zanzibar) using an area-wide integrated pest manage-
ment approach including the sterile insect technique (SIT)
(1994–1997) [5] encouraged several African countries to
incorporate the SIT in their national tsetse control programs.
A facility to produce sterile flies for SIT application in the
Southern Rift Valley of Ethiopia was inaugurated in 2007 [6].
A Glossina pallidipes colony was initiated with wild flies from the
target area but colony build-up was hampered due to the high
prevalence (26–40%) of salivary gland hypertrophy (SGH)
syndrome in the flies [7,8]. Similar cases were reported at the
FAO/IAEA Insect Pest Control Laboratory, Seibersdorf, Austria
where 2 colonies of G. pallidipes with a SGH prevalence up to
85% collapsed in 1987 and 2001. G. pallidipes flies with SGH
have no or reduced progeny and could jeopardize eradication
programs with an SIT component against this species.
The causative agent of SGH, the G. pallidipes salivary gland
hypertrophy virus (GpSGHV), is a nuclear, rod-shaped, enveloped
dsDNA virus averaging 706640 nm in size that infects various
tissues in tsetse but hypertrophy symptoms appear only in salivary
glands [9–15]. The virus in wild tsetse populations is transmitted
vertically from mother to progeny either by transovum transmis-
sion or to developing larvae through infected milk glands, whereas
under laboratory conditions horizontal transmission of the virus
through the in vitro blood feeding technique is the main source of
infection [8,16]. As much as 10
7 virus particles per ml can be
deposited by a single heavily infected fly via salivary secretions into
the blood and this virus could easily be taken up by other,
uninfected flies [8]. These data, along with the complete
sequencing of the viral genome [17] provided guidance to
potential strategies for controlling GpSGHV in tsetse laboratory
or mass-reared colonies [8]. Several strategies are under investi-
gation including (i) clean feeding where each cage of flies is offered
unused (fresh) blood, and (ii) commercial antiviral drugs added to
the blood diet to reduce virus replication [18].
The discovery in the late 1970s that acyclic nucleoside
analogues, in particular acyclovir, could inhibit DNA replication
of herpes simplex virus (HSV) at concentrations far below those
that affect cellular DNA synthesis sparked a new era in antiviral
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that acyclovir is specifically converted to the active metabolite by
an HSV-encoded thymidine kinase – was unexpected but the
potential for exploiting viral enzymes to develop potent and
specific antiviral drugs was clearly demonstrated. Acyclovir
subsequently became a successful treatment for HSV-1 and
HSV-2 [19–21]. Later, many antiviral drugs that inhibit the DNA
polymerase of herpes viruses were developed and tested. After
completing the genome sequence of GpSGHV, phylogenetic
analysis of its DNA polymerase amino acid sequence revealed that
it shares the highest similarity with herpes virus DNA polymerase
[17]. These similarities led us to speculate that the antiviral drugs
against herpes viruses might inhibit or reduce GpSGHV
replication and prompted research to assess the feasibility of using
these antiviral drugs to manage the GpSGHV infection in colonies
of G. pallidipes. Here we present the results of evaluating two
antiviral drugs, acyclovir and valacyclovir, currently used against
herpesviruses, for their ability to suppress viral infection and SGH
symptoms in colonies of G. pallidipes. Valacyclovir is the L-valyl
ester of acyclovir and has shown to have a better bioavailability
and oral absorption in HSV treatments [19–21].
Figure 1. Dose effect of Acyclovir and Valacyclovir on tsetse flies G. pallidipes productivity and mortality. Flies were fed on blood
supplemented with different concentrations (10 to 1000 mg/ml) of the two antiviral drugs for 60 days and the produced pupae (A) and mortality (B)
were recorded. Flies fed with drug-free blood were used as control.
doi:10.1371/journal.pone.0038417.g001
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Effect of Valacyclovir and Acyclovir on the Fly Biology
The impact of valacyclovir and acyclovir when given orally in
the blood diet on tsetse fly reproduction and survival was tested at
different concentrations (10–1000 mg/ml) of each of the two drugs
in Experiment 1. After treatment, fly fecundity and mortality were
checked. The highest concentration (1000 mg/ml) of both
acyclovir and valacyclovir significantly reduced the fecundity
expressed as the number of pupae produced per initial female
(PPIF) (Fig. 1A). At concentrations lower than 1000 mg/ml, no
significant differences were observed in PPIF between the drug-
treated and non-treated flies (P=0.348), nor among the different
concentrations of the drugs (P=0.104). The mortality rate after 60
days of acyclovir-treated flies averaged 20% regardless of the drug
concentration, with the unexplained exception of flies treated with
300 mg/ml where a significantly lower mortality was recorded
(Fig. 1B). Conversely, the mortality rate after 60 days in
valacyclovir-treated flies decreased proportionally with increasing
drug concentration. While at low concentration (10 mg/ml)
mortality in the treated flies averaged 20% after 60 days, at the
highest concentration (1 mg/ml) only 8% mortality was recorded
(Fig 1B). Similar to the productivity, no significant differences in
mortality were observed between antiviral drug treated and non-
treated flies (P=0.149) or among the different concentrations of
the drugs (P=0.118). Based on these data, the 300 mg/ml
concentration appeared to be the most efficient concentration to
block virus replication and was selected for subsequent experi-
ments.
Effect of Valacyclovir and Acyclovir Treatment on SGHV
Load and SGH Prevalence
In experiment 2, the impact of the two drugs on SGHV
replication was analyzed by feeding samples of 60 flies (45 females
and 15 males) in three replicates with blood containing 300 mg/ml
of acyclovir or valacyclovir for three successive fly generations in
combination with clean feeding and measuring the virus loads by
qPCR. A significant reduction (P,0.0001) in virus load was
observed between generations following both treatments (Fig. 2).
Virus loads in all F2 generation flies treated either with acyclovir
or valacyclovir were clearly under the threshold of 10
9 copy
number measured for flies with hypertrophied salivary gland [22].
A similar reduction in virus load was however detected in the
control flies in the F2, consistent with our previous report of a
reduced virus load in flies fed only on fresh blood using clean
feeding for three generations [8].
To further distinguish which of the two factors, antiviral drug or
clean feeding, was responsible for the reduction of the virus load, 3
groups of G. pallidipes flies with initial low viral load (as measured
according to [22]) were maintained for 19 months either under
clean feeding conditions or on blood deliberately contaminated
with virus and supplemented or not with the antiviral drugs
(experiment 3). During the experiment we observed that long term
feeding of the flies with blood supplemented with acyclovir
progressively reduced fly fecundity (PPIF) over time. The group of
acyclovir-treated flies was, therefore, removed from the experi-
ment after 28 weeks. In the group fed with blood supplemented
with valacyclovir, acceptable rates of productivity (P=0.432) and
mortality (P=0.162) were maintained through several generations
without a significant difference between treated and non-treated
flies (Fig. 3A).
With respect to the impact of long term treatment with
valacyclovir on SGHV replication, we observed a significant
reduction in SGH symptoms (P,0.001) (Table 1) to an overall
average of 0.63% (4/633, from 24 samples) after 83 weeks of the
treatment whereas in the untreated group fed on contaminated
blood, SGH prevalence averaged 5.62% (43/765) with a
maximum of 19% (Fig. 3B – positive control). The application
Figure 2. Effect of antiviral drug treatments in combination with clean feeding on the SGHV load in tsetse flies over three
generations. At each generation flies were fed on blood supplemented with 300 mg/ml antiviral drug for 60 days, then virus load was estimated by
qPCR as previously reported [22]. Flies fed with drug-free blood were used as control.
doi:10.1371/journal.pone.0038417.g002
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1.9% (22/1154) (Fig. 3B) negative control). These results clearly
demonstrated that valacyclovir alone suppressed GpSGHV
replication (P,0.001) and maintained the virus infection far
below the threshold level of 10
9 viral copies required to develop
SGH in G. pallidipes [22]. The overall effect of valacyclovir on
GpSGHV replication mimics that of this drug in controlling
herpesvirus infections in humans. It suppresses the symptom of
SGH but does not eradicate the virus from the colony. This
suggests a similar mode of action leading to the specific inhibition
of the GpSGHV DNA polymerase through a pathway which
remains to be elucidated. In contrast to herpesviruses, no gene
homologous to a thymidine kinase has been identified in the
GpSGHV genome [17]. The prodrug is, thus, very likely
phosphorylated by a cellular thymidine kinase assumed to be
particularly abundant in infected cells where active viral DNA
replication occurs. The absence of negative side effects of the drug
on productivity (P=0.432) and survival (P=0.162) of G. pallidipes
during long term administration (2.5 years) supports the idea of
using the drug for large-scale rearing of G. pallidipes. Moreover, the
relatively cheap price of this drug compared to the high cost of
clean feeding makes its application economically attractive. The
reduced fecundity of flies subjected for an extended period to
acyclovir treatment only is difficult to explain, especially since we
previously reported that most of the valacyclovir ingested by the
flies is converted to acyclovir [23], as is the case for vertebrates. In
vertebrates, this conversion is known to occur rapidly in both the
intestine and liver. In contrast nothing is known on the site and
rate at which the cleavage of valacyclovir occurs in tsetse flies. The
availability of acyclovir in the flies and the peak haemolymph
concentration will depend on the concentration fed, the rate of
uptake, breakdown and excretion whereas the availability of the
active moiety (acyclovir) in the flies fed valacyclovir will also
depend on the rate of conversion of valacyclovir to acyclovir. It
might be speculated that the availability of a high concentration of
acyclovir can have a negative impact on host DNA replication,
especially in the embryonic phase when a high rate of DNA
replication is required for cell division. Blockage of the DNA
polymerase activity in this embryonic phase will affect the flies’
productivity. A possible explanation of the lack of these negative
side effects in valacyclovir-treated flies is that the conversions rate
of valacyclovir to acyclovir probably maintains the peak haemo-
lymph concentration at a lower level than in the acyclovir
treatment.
Effect of Combination of Valacyclovir and Clean Feeding
on SGH Prevalence
Previous work had shown that the virus load in asymptomatic
and symptomatic females flies determined to a large extend the
prevalence of symptomatic infection in their progeny (2) and that
flies with SGH excrete several orders of magnitude more virus
particles when feeding than asymptomatic flies [8]. Furthermore,
results of experiments 2 and 3 indicated that valavcyclovir
treatment whether alone or combined with clean feeding reduced
the SGH prevalence in the treated colonies overtime [8]. An
experiment was, therefore, set up to assess the effect of the various
treatments on teneral flies screened negative for virus infection so
as to eliminate or reduce flies SGH in the progeny.
Combining pre-selection of flies, clean feeding and valacyclovir
treatment resulted in the complete elimination of SGH from
treated flies in less than 33 weeks.(Fig. 4), corresponding to
approximately 2–3 generations. In the absence of the preselection
of negative teneral flies, clean feeding alone or in combination with
valacyclovir treatment reduced but did not eliminate the SGH
after 60 weeks. The results also showed that although the SGH
prevalence in valacyclovir-treated and untreated flies was not
significantly different (P=0.712), the difference between screened
and unscreened flies was significant (P,0.003).
This result are quite important in case the colony manager -due
to some difficulties to start a new colony from wild collected flies-
needs to establish a new colony with a low virus load from an
existing colony infected with the SGHV. Our results indicate that
combining pre-selection of flies for SGHV, clean feeding and
valacyclovir treatment will significantly reduce the time needed to
Figure 3. Effect of long term treatment with valacyclovir on G. pallidipes biology and virus prevalence. (A) Productivity (PPIF) and
mortality of flies fed on blood supplemented with 300 mg/ml antiviral drug for 60 days. (B) SGHV virus load and SGH prevalence by qPCR and
dissection, at 60 days after feeding. (---): threshold virus load correlated with SGH symptoms. Negative control: flies fed exclusively on clean blood;
positive control: Flies fed on virus contaminated blood; valacyclovir: flies fed on virus contaminated blood with 300 mg/ml valacyclovir.
doi:10.1371/journal.pone.0038417.g003
Table 1. Effect of valacyclovir on the incidence of salivary gland hypertrophy in Glossina pallidipes, analysis of variance and
pairwise comparison of treatment means.
Mean
a Variance Detransformed mean
Valacyclovir 0.022499 0.003948 0.000506
Positive control 0.15367 0.023355 0.023429
Negative control 0.100026 0.011388 0.009972
VP N
V
b ** *
P 5.87
c n.s.
N 3.52 2.51
F=8.66.
d.f.=2, 80.
P=0.00039.
T values for comparison of means.
aProportions were angular transformed before analysis.
bV=valacyclovir, P=positive control, N=negative control.
cTransformed means
were compared by the Tukey-Kramer HSD for unequal sample sizes.
doi:10.1371/journal.pone.0038417.t001
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infections.
Conclusion
In conclusion, our results show that long term treatment of
tsetse colonies with valacyclovir fulfills the four requirements of (i)
absence of any significant negative effect on fly survival and
productivity, (ii) significant reduction of virus load, (iii) suitable
bioavailability when offered to the flies mixed with blood and (iv)
affordable price. These requirements have to be considered for use
in large scale tsetse rearing facilities.
Important fundamental and practical questions remain to be
addressed such as the mode of action of valacyclovir on virus
replication, how long the treatment should be maintained to keep
the virus load low in the colony and how long the flies can tolerate
the drug treatment without hampering on their productivity and
mortality. Nevertheless, our data offer a solution to sustain SGHV-
infected colonies of G. pallidipes and provide the colony manager an
alternative to the very long and expensive process of establishing a
new colony from field caught flies that probably is not free of virus.
Materials and Methods
Strains and Experimental Conditions
All experiments were carried on a G. pallidipes colony originating
from pupae collected in Tororo, Uganda in 1975 and initially
colonized in The Netherlands. These flies were transferred to the
Insect Pest Control Laboratory, Seibersdorf, Austria in 1982. The
colony adults were fed on heated, defibrinated bovine blood
(SVAMAN spol s.r.o., Myjava, 90701, SLOVAKIA) for 10–
15 min three times per week using a membrane feeding technique.
Each feeding tray with blood and membrane was used to feed up
to six sets of cages successively, starting with the youngest flies [24].
The deposited larvae pupate and were incubated at 24uC until
emergence. Previous analysis revealed that ca 4–10% of individ-
uals in the colony showed SGH [25].
Treatments of Flies with Antiviral Drugs and Toxicity
Tests (Experiment 1)
Acyclovir (95% purity) and valacyclovir-HCl (96% purity) (both
from Molekula, UK), were used to prepare standard solutions in
distilled water. Teneral tsetse flies (30 females and 10 males per
replicate) were fed either with blood meals containing different
Figure 4. Effect of the combination of clean feeding, screening flies with non-destructive PCR for virus infection and valacyclovir
treatment on the expression of SGH syndrome. Screened: teneral flies were tested with non-destructive PCR and only negative flies were used.
Non-screened: teneral flies with natural variable virus infection load were used. Flies were fed on blood supplemented or not with 300 mg/ml antiviral
drug for 60 days, then virus load was estimated by qPCR.
doi:10.1371/journal.pone.0038417.g004
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replicates.
The effect of different concentrations of acyclovir and
valacyclovir-HCl (from 30 to1000 mg/ml of blood) on fly fecundity
measured as the number of pupae produced per initial female
(PPIF), mortality and SGHV copy number as previously described
[22] was analyzed by feeding the flies on blood with either drug
three times per week for 30 days.
Long Term Use of Drugs (Experiment 2)
To analyze the impact of the long term use of the drugs on fly
biology, SGH prevalence and virus loads, teneral flies (45 females
and 15 males in each of three replicates) were fed on blood
supplemented with either of the two drugs at 300 mg/ml for 60
days. Pupae from the treated flies were collected and flies emerging
from F1 pupae (and subsequent F2 pupae) were treated in a
similar way (60 days each generation). Samples of 16 flies/
replicate were selected from each treatment and generation for
qPCR and the remaining number of flies were dissected and the
SGH statue was recorded. To quantify the virus load in
experimental flies genomic DNA was extracted from whole flies
using DNeasy kit (Qiagen) following the supplier’s instructions and
used for qPCR analysis according to previously described
conditions [8,22].
Clean Feeding and Contaminated Blood
For all tests using the clean feeding system, the feeding trays
(membranes and blood) were changed after each set of cages to
eliminate the possibility of horizontal virus transmission from one
set of cages to another. For the positive control group, three sets of
cages of 45 day-old tsetse flies from the standard colony (infected
with the virus) were fed with blood first on each membrane to be
used in the experiment to deliberately contaminated the blood
with virus [8] before each feeding the experimental flies.
Effect of Antiviral Drugs on the Suppression of SGH
Expression and Virus Load (Experiment 3)
To distinguish between the impact of the drugs and the effect of
clean feeding on SGH prevalence, teneral flies from the F2
progeny of experiment 2 (with low virus load, see results) were fed
either with clean or contaminated blood or with contaminated
blood containing valacyclovir at a concentration of 300 mg/ml for
83 weeks. Emerged flies were collected in weekly units, or when
not enough flies were collected, the flies emerged over two weeks
were collected together. Pupae from the treated and untreated flies
were collected on a weekly basis as previously described [26]. The
flies were tested for virus load using qPCR and dissected for SGH
prevalence when they reached 60 days of age.
Effect of Combination of Valacyclovir Treatment, Clean
Feeding and Screening on the Suppression of SGH
Expression (Experiment 4)
A first set of teneral flies screened negative for virus infection
using non-destructive PCR [25] were selected and divided into
two groups : (i) the first group fed on clean blood and designated as
(Screen-Clean feeding), the second group (ii) fed on blood with
valacyclovir (300 mg/ml) and designated (Screened-Vala).
A second set of non-screened teneral flies were divided into two
groups, (iii) fed on clean blood and designated as (non-screened-
clean feeding) and (iv) fed on blood with valacyclovir and
designated as (non-screened-Vala). Flies (15 males and 45 females
per replicate) were maintained and fed for 60 days and then
dissected to record the status of the salivary glands.
Statistical Analysis
Proportions (mortality and hypertrophy) were angular trans-
formed. Treatments were analyzed by ANOVAR and individual
treatment means compared with the Tukey-Kramer HSD test
[27]. Analysis was performed using ExcelH 13 (Microsoft Corp.),
RExcel [28] and R [29].
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